A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma

BACKGROUND: Vascular endothelial growth factor A (VEGF-A) is important in the pathogenesis of Kaposi sarcoma (KS), and bevacizumab has response rate of 31%. We explored the combination of bevacizumab with liposomal doxorubicin in patients with KS. METHODS: KS patients requiring systemic therapy were...

Full description

Saved in:
Bibliographic Details
Published in:Clin Cancer Res
Main Authors: Ramaswami, Ramya, Uldrick, Thomas S., Polizzotto, Mark N., Wyvill, Kathleen M., Goncalves, Priscila, Widell, Anaida, Lurain, Kathryn, Steinberg, Seth M., Figg, William Douglas, Tosato, Giovanna, Whitby, Denise, Yarchoan, Robert
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6635024/
https://ncbi.nlm.nih.gov/pubmed/30979736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3528
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items